OCM
IMRX icon

Occam Crest Management’s Immuneering IMRX Stock Holding History

Occam Crest Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Sell
278,498
-266,600
-49% -$1.35M 0.59% 27
2026
Q1 		$2.87M Buy
545,098
+46,600
+9% +$239K 1.74% 20
2025
Q4 		$3.28M Hold
498,498
– – 2.28% 15
2025
Q3 		$3.49M Buy
+498,498
New +$2.59M 2.12% 15

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Occam Crest Management's IMRX Position: Q2 2026 in Review

Occam Crest Management reduced its Immuneering (IMRX) stake by 49% in Q2 2026, selling an estimated $1.35M and leaving 278,498 shares worth $1.13M. The position accounts for 0.59% of the portfolio, ranked #27.

Occam Crest Management first reported a position in IMRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.49M in Q3 2025. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Occam Crest Management held 278,498 shares of Immuneering worth $1.13M as of Q2 2026.
  • Occam Crest Management sold 266,600 Immuneering shares in Q2 2026, an estimated $1.35M.
  • Immuneering made up 0.59% of Occam Crest Management's portfolio in Q2 2026, its #27 holding.
  • Occam Crest Management first reported a position in Immuneering in Q3 2025 and has held it in 4 quarters since.
  • Occam Crest Management's Immuneering position peaked at $3.49M in Q3 2025.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Occam Crest Management's 13F filing for Q2 2026, filed 14 Aug 2026.